MedDataX Logo

tACS Treatment for Cognitive Impairments in Methamphetamine Addicts

NCT ID: NCT06292156

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-30

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To evaluate the cognitive function of methamphetamine Patients.
2. Investigate the pathological mechanism of methamphetamine patients from the aspects of EEG and biology;
3. The investigators investigated the effects of transcranial alternating current stimulation (tACS) on cognitive impairments in methamphetamine patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methamphetamine Abuse

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Methamphetamine patients Cognitive impairments tACS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Theta treatment group

In active tACS, the target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3 consecutive weeks.

Group Type EXPERIMENTAL

Theta treatment group

Intervention Type DEVICE

The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks

Sham control group

In sham group, Sham stimulation lasted 30 s (15 s of ramp- up and 15 of ramp-down) .

Group Type SHAM_COMPARATOR

Sham control group

Intervention Type DEVICE

Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Theta treatment group

The target 'active' electrode was placed over the MFC and the second 'return' electrode was placed over the medial parietal cortex. 6 Hz stimulation was used and a alternating current of 2mA was applied for 30min each day(Monday-Friday) for 3consecutive weeks

Intervention Type DEVICE

Sham control group

Sham stimulation lasted 30 s (15 s of ramp- up and 15 s of ramp-down).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis diagnosis of methamphetamine use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
* None of participants had mixed use of other drugs
* None of participants had physical disability
* None of participants had acute physical or mental illness, hallucinations, acute withdrawal symptoms
* None of participants were receiving any medical treatment

Exclusion Criteria

* Intracranial hypertension
* Cranial defects
* Tumors
* Serious physical illnesses (e.g., cardiovascular, liver, kidney, gastrointestinal disorders)
* Infectious diseases
* Immune system disorders
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing HuiLongGuan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiang Yang Zhang

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xin Hua Drug Rehabilitation Center

Mianyang, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CASPsy7

Identifier Type: -

Identifier Source: org_study_id